Market closed

Cyclo Therapeutics/$CYTH

14:30

16:10

17:45

19:25

21:00

1D1W1MYTD1Y5YMAX

About Cyclo Therapeutics

Cyclo Therapeutics Inc is a clinical-stage biotechnology firm. The company is engaged in developing cyclodextrin-based products for treating neurodegenerative diseases, particularly Niemann-Pick Type C disease (NPC). The company's lead drug candidate, Trappsol Cyclo, has undergone clinical trials for NPC treatment. Operating in one segment, the company focuses on developing and commercializing cyclodextrin-based treatments for rare diseases. Revenue primarily comes from selling cyclodextrins and related products to pharmaceutical and nutritional industries, with Trappsol HPB and Trappsol Fine Chemical being significant contributors.

Ticker

$CYTH

Sector

Health Care

Trading on

NASDAQ

Industry

Biotechnology

Headquarters

Gainesville, United States

Employees

Website

cyclotherapeutics.com

CYTH Metrics

BasicAdvanced

$20M

-

-$0.92

-0.38

-

Price and volume

Market cap

$20M

Beta

-0.38

52-week high

$2.12

52-week low

$0.55

Average daily volume

50K

Financial strength

Current ratio

0.174

Quick ratio

0.06

Long term debt to equity

-0.053

Total debt to equity

-90.588

Management effectiveness

Return on assets (TTM)

-284.27%

Return on equity (TTM)

341.45%

Valuation

Price to revenue (TTM)

21.117

Price to book

-1.45

Price to tangible book (TTM)

-1.45

Price to free cash flow (TTM)

-0.816

Growth

Revenue change (TTM)

-8.52%

Earnings per share change (TTM)

-38.93%

3-year revenue growth (CAGR)

-8.76%

3-year earnings per share growth (CAGR)

-31.13%

What the Analysts think about CYTH

Analyst Ratings

Analyst ratings (Buy, Hold, Sell) for Cyclo Therapeutics stock.

CYTH Financial Performance

Income Statement

Revenues and expenses

QuarterlyAnnual

Q3 24

QoQ growth

Revenue

$37B

-39.75%

Net income

$45B

107.52%

Profit margin

37.65%

6.78%

CYTH Earnings Performance

Earnings per share (EPS)

Company profitability

QuarterlyAnnual

Q4 23

Q1 24

Q2 24

Q3 24

Q4 24

Actual

$3.69

$2.85

$2.45

$2.42

-

Expected

$3.55

$2.61

$2.05

$2.31

$3.94

Surprise

3.94%

9.20%

19.51%

4.63%

-

CYTH News

AllArticlesVideos

Niemann-Pick Disease Pipeline Market Research 2024: Comprehensive Insights about 12+ Drugs Featuring Cyclo Therapeutics, Azafaros, IntraBio

GlobeNewsWire·2 months ago

Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.

Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $CYTH

$

Capital at risk

Market closed

Upcoming events

No upcoming events

FAQs

What’s the current market cap for Cyclo Therapeutics stock?

Cyclo Therapeutics (CYTH) has a market cap of $20M as of January 15, 2025.

What is the P/E ratio for Cyclo Therapeutics stock?

The price to earnings (P/E) ratio for Cyclo Therapeutics (CYTH) stock is 0 as of January 15, 2025.

Does Cyclo Therapeutics stock pay dividends?

No, Cyclo Therapeutics (CYTH) stock does not pay dividends to its shareholders as of January 15, 2025.

When is the next Cyclo Therapeutics dividend payment date?

Cyclo Therapeutics (CYTH) stock does not pay dividends to its shareholders.

What is the beta indicator for Cyclo Therapeutics?

Cyclo Therapeutics (CYTH) has a beta rating of -0.38. This means that it has an inverse relation to market volatility.